Court Outcomes May Affect Some Authorized Generic Deals

Drug Industry Daily
KEYWORDS courts / Patents

The U.S. Supreme Court has asked the Department of Justice (DOJ) to weigh in on a case that could make it harder for brand drugmakers to settle patent disputes through the use of authorized generics. Meanwhile, another antitrust case that was decided last week could have even greater consequences for the practice, one legal expert told DID.

To View This Article:


Subscribe To Drug Industry Daily